Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Deferred and other income taxes

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxesAndTaxCredits.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's deferred and other income taxes.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's deferred and other income taxes?
Charles River Laboratories (CRL) reported deferred and other income taxes of -$29.42M in Q1 2026.
How has Charles River Laboratories's deferred and other income taxes changed year-over-year?
Charles River Laboratories's deferred and other income taxes decreased by 54.5% year-over-year, from -$19.04M to -$29.42M.
What is the long-term trend for Charles River Laboratories's deferred and other income taxes?
Over 3 years (2021 to 2024), Charles River Laboratories's deferred and other income taxes has grown at a 41.1% compound annual growth rate (CAGR), from -$24.01M to -$67.43M.